NICE tackles blood clots
This article was originally published in Scrip
New guidelines on venous thromboembolism (VTE) should drastically cut the number of preventable deaths in the UK caused by hospital-acquired VTE, thought to reach around 25,000 each year. Pharmacological prophylaxis will play a prominent a role.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.